Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 1,2,3,4-Tetrahydroisoquinoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.73 |
| ▸ | CD44 | P16070 | 1/20 | 0.73 |
| ▸ | MAOB | P27338 | 1/20 | 0.73 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL6010101 | 0.92 | PNMT (0.79) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL8522585 | 0.91 | PNMT (0.70) | PNMTCD44MAOBHTR2C | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL4779021 | 0.90 | PNMT (0.76) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL6647088 | 0.89 | PNMT (0.73) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL16291557 | 0.88 | PNMT (0.86) | PNMTCD44MAOBHTR2C | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29210287 | 0.87 | PNMT (0.66) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28236302 | 0.85 | PNMT (1.00) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29360217 | 0.85 | PNMT (1.00) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL19085 | 0.85 | PNMT (1.00) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL11441365 | 0.85 | PNMT (0.68) | PNMTCD44MAOBHTR2CPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230324392-A1 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-10-12 | — | — | US | claimed |
| EP-4208572-A1 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | Memorial Sloan Kettering Cancer Center (US) | 2023-07-12 | — | — | EP | claimed |
| WO-2006091506-A2 | NEUROPEPTIDE Y4 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | WO | claimed |
| US-20230324392-A1 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4208572-A1 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | Memorial Sloan Kettering Cancer Center (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| EP-1689421-A4 | SELECTIVE NEUROPEPTIDE Y2 RECEPTOR AGONISTS | BAYER HEALTHCARE AG (DE) | 2009-06-24 | — | — | EP | disclosed |
| CN-101454281-A | Prostaglandin ep4 agonists | ALLERGAN INC (US) | 2009-06-10 | — | — | CN | disclosed |
| US-20090105122-A1 | Selective neuropeptide y2 receptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1896048-A2 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | Bayer Pharmaceuticals Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1883419-A2 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | Bayer Pharmaceuticals Corporation (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1368340-A1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1368339-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1358163-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003061660-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002059095-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059107-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059117-A1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059108-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| CN-1183773-A | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds | UPJOHN CO (US) | 1998-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | PNMT 2177/4885CD44 4372/4885MAOB 2611/4885 |
| US-20090105122-A1 | Selective neuropeptide y2 receptor agonists | NPY2R, NPY1R, NPY4R | PNMT 761/4885CD44 4799/4885MAOB 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.